New COPD drug tested across chinese, japanese, and european volunteers

NCT ID NCT06979518

Completed Knowledge-focused Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tested a single dose of the experimental drug GSK3862995B in 30 healthy adults of Chinese, Japanese, and European ancestry. The goal was to see if the drug is processed similarly across these groups, so that future global COPD studies can include diverse participants. Researchers monitored safety, side effects, and drug levels in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GSK3862995B
What this could lead to: If successful, this study could help include Chinese and Japanese participants in future global trials for chronic obstructive pulmonary disease treatments.
What could go wrong: This is an early phase 1 safety study with only 30 healthy people, so it cannot yet show if the drug works for COPD. Results may not apply to patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY DISEASE, CHRONIC OBSTRUCTIVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PULMONARY DISEASE, CHRONIC OBSTRUCTIVE

Contacts and locations

Locations

GSK Investigational Site

Cypress, California, 90630, United States
GSK Investigational Site

Las Vegas, Nevada, 89113, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.